Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
相关临床试验
23
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2012
进行中（未招募）
10
43.5%
已完成
4
17.4%
Enrolling By Invitation
1
4.3%
招募中
1
4.3%
终止
6
26.1%
撤回
1
4.3%
暂无批准数据
- Novartis discontinued development of VHB937 (lifonebart) after the Phase 2 ASTRALS trial in early-stage ALS missed both primary and secondary endpoints. - The 251-patient trial tested the TREM2-stabilizing monoclonal antibody or placebo for 40 weeks, with no numerical data released by the company. - The setback adds to a difficult pipeline stretch for Novartis, following Phase 3 misses for pelacarsen and del-desiran and halted rap-cel studies. - Detailed ASTRALS findings are scheduled for presentation at the 37th International Symposium on ALS/MND in Amsterdam on December 9-11, 2026.
- Moonwalk Biosciences closed an oversubscribed $70 million Series B financing to develop first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases. - Proceeds will advance lead candidate MW101 into first-in-human studies in late 2027 and expand the company's tissue-targeted siRNA pipeline and discovery platform. - Preclinical studies demonstrated reductions in body weight and fat mass while preserving lean muscle and without reducing food intake, supporting potential quarterly or twice-yearly dosing. - The non-incretin approach positions Moonwalk apart from GLP-1 therapies, with backing from Eli Lilly, Alpha Wave, YK Bioventures, and other investors.
- Wave Life Sciences is a clinical-stage genetic medicine company developing stereopure oligonucleotides using its proprietary PRISM platform to target RNA and modulate gene expression. - The pipeline includes candidates for ALS, Huntington's disease, Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and inherited retinal conditions such as Usher syndrome type 2A. - The company has established collaborations with Pfizer and Takeda, providing funding and licensing support while it remains pre-revenue with no commercialized products. - Success hinges on advancing candidates through clinical milestones, securing regulatory guidance, and managing capital in a competitive genetic medicine landscape.
- GSK has returned global rights to WVE-006, the most advanced RNA editing medicine in clinical testing, to Wave Life Sciences after underwhelming Phase Ib/IIa results in alpha-1 antitrypsin deficiency. - The September 2024 trial data showed 11.9uM of alpha-1 antitrypsin protein levels with 200-mg dosing, falling just short of the 12uM threshold expected by analysts. - Wave plans to accelerate regulatory submissions and seek FDA guidance on accelerated approval pathways, with additional data from higher doses expected in Q1 2026. - The broader GSK-Wave collaboration continues with up to $2.8 billion in potential milestones across eight preclinical programs using Wave's PRISM platform.
- Eight biotech companies raised a record $3.5 billion in a single night following the American Society of Hematology conference, marking the busiest day ever in biotech fundraising. - Terns Pharmaceutical led the surge with a $650 million offering after presenting Phase I leukemia trial data showing 64% response rates, with potential peak sales projected at $2.5 billion. - Fulcrum Therapeutics raised $175 million following positive Phase Ib results for its sickle cell disease treatment in expectant mothers, demonstrating meaningful increases in fetal hemoglobin levels. - The fundraising wave reflects strong biotech sector performance with the NYSE Arca Biotechnology Index up 27% year-to-date, driven by positive trial results and increased M&A activity.
- Wave Life Sciences reported that its investigational weight loss drug WVE-007 reduced total body fat by 4.5% over three months in a phase 1 clinical trial, outperforming semaglutide at the same development stage. - The treatment demonstrated a compelling safety and tolerability profile without the muscle loss associated with GLP-1 drugs like Wegovy, according to CEO Paul Bolno. - The positive interim data triggered a remarkable 146% surge in Wave Life Sciences' stock price, reflecting strong investor enthusiasm for obesity therapeutics. - While promising, the drug remains in early development stages and regulatory approval is not guaranteed despite the encouraging clinical results.
- Dyne Therapeutics plans to seek accelerated U.S. approval for z-rostudirsen, an exon skipping therapy that increased muscle-protecting protein levels by more than 5% in Duchenne muscular dystrophy patients with exon 51 mutations. - Kymera Therapeutics shares rose over 50% following positive data for KT-621, an oral protein-degrading drug showing "biologic-like or better efficacy" in atopic dermatitis markers. - Wave Life Sciences stock nearly doubled after WVE-007 demonstrated a 9% reduction in visceral fat and 4% decline in total body fat in early obesity trials. - Despite regulatory uncertainties in the Duchenne field, analysts noted Dyne's functional data represents the "best ever generated" for this drug class in placebo-controlled trials.
- The Duchenne Muscular Dystrophy market reached approximately $2.15 billion in 2023 and is expected to grow significantly due to increased drug uptake and anticipated gene therapy launches. - Over 75 companies are actively developing pipeline therapies for DMD, with recent FDA designations including Atossa Therapeutics' (Z)-Endoxifen receiving Rare Pediatric Disease designation. - Capricor Therapeutics announced positive Phase 3 HOPE-3 trial results for Deramiocel, while the FDA accepted their BLA for review with Priority Review designation. - Current approved treatments include EMFLAZA, VYONDYS 53, EXONDYS 51, AMONDYS 45, VILTEPSO, and gene therapy ELEVIDYS in the US, with AGAMREE launched in Germany in 2024.
- Korro Bio's lead RNA editing therapy KRRO-110 for alpha-1 antitrypsin deficiency failed to produce functional protein at expected levels in early clinical testing. - The company is abandoning its lead program and laying off 34% of staff while shifting to a new delivery approach using sugar molecules. - The setback leaves Korro behind competitors Wave Life Sciences and Airna in the RNA editing space for AATD treatment. - Korro's research collaboration with Novo Nordisk for cardiometabolic diseases has been paused for 12 months to reassess the program.
- Wave Life Sciences announced dose-dependent Activin E reductions of up to 85% one month after a single dose of WVE-007 in the INLIGHT clinical trial for obesity treatment. - The reductions observed in higher dose cohorts exceeded levels that led to weight loss in preclinical models, with sustained effects lasting six months in the lowest dose cohort. - WVE-007 demonstrated a favorable safety profile and aims to achieve fat loss comparable to semaglutide through a novel INHBE silencing mechanism that preserves muscle mass. - The company also advanced its RNA editing pipeline with WVE-008 for liver disease and announced plans for multiple clinical data updates starting in Q4 2025.
